ORIGINAL ARTICLE
The association of tumor lymphocyte infiltration with clinicopathological factors and survival in breast cancer
 
More details
Hide details
 
Submission date: 2016-05-27
 
 
Final revision date: 2017-01-28
 
 
Acceptance date: 2017-01-30
 
 
Publication date: 2017-05-23
 
 
Pol J Pathol 2017;68(1):26-32
 
KEYWORDS
TOPICS
ABSTRACT
Recent studies have confirmed the role of tumor-infiltrating lymphocytes (TILs) in carcinogenesis and cancer progression. The aim of this study was to evaluate the correlation between the level of tumor lymphocyte infiltration and well-known clinicopathological factors in breast cancer patients. We also evaluated the influence of TILs on overall survival. Paraffin sections were retrospectively evaluated in 76 cases in early stage breast cancer patients who underwent surgery followed by systemic treatment. Tumor-infiltrating lymphocytes were classified as absent (grade 0), mild (grade 1), moderate (grade 2), or severe (grade 3). Tumor-infiltrating lymphocytes were found in 87% of patients (severe grade in 8% of them). Higher grade (grades 2-3) TILs were present more frequently in younger patients (under 65 years) than older women (47% vs. 24%; p = 0.099). Higher grades of tumor-infiltrating lymphocytes (grades 2-3) appear to be associated with clinicopathological factors such as negative steroid receptor status (p = 0.001), HER2 overexpression (p = 0.016) and higher histological grade (G3) (p = 0.095). Tumor-infiltrating lymphocytes were not a significant prognostic factor for overall survival in our group. Only HER2 overexpression significantly increases the risk of death (HR = 4.3, p = 0.020). In the subgroup of patients who had tumors with HER2 overexpression there was non-significantly worse OS independently of TIL grade (p = 0.086).
REFERENCES (21)
1.
Yersal O, Barutca S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J Clin Oncol 2014; 5: 412-424.
 
2.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
 
3.
Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity 2014; 41: 49-61.
 
4.
Raggi C, Mousa HS, Correnti M, Sica A, Invernizzi P. Cancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategies. Oncogene 2016; 35: 671-682.
 
5.
Perdiguero EG, Geissmann F. Cancer immunology. Identifying the infiltrators. Science 2014; 344: 801-802.
 
6.
Korkaya H, Liu S, Wicha MS. Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest 2011; 121: 3804-3809.
 
7.
Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28: 105-113.
 
8.
Kohrt HE, Nouri N, Nowels K, et al. Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med 2005; 2: e284.
 
9.
Issa-Nummer Y, Darb-Esfahani S, Loibl S, et al. Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer – a substudy of the neoadjuvant GeparQuinto trial. PLoS One 2013; 8: e79775.
 
10.
Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 2013; 31: 860-867.
 
11.
Loi S, Michiels S, Salgado R, et al. Tumor infiltrating lymphocytes is prognostic and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 2014; 25: 1544-1550.
 
12.
Mahmoud SM, Paish EC, Powe DG, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011; 29: 1949-1955.
 
13.
West NR, Milne K, Truong PT, et al. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res 2011; 13: R126.
 
14.
Ali HR, Provenzano E, Dawson SJ, et al. Association between CD8+T cell infiltration and breast cancer survival in 12 439 patients. Ann Oncol 2014; 26: 1536-1543.
 
15.
Yu X, Zhang Z, Wang Z, et al. Prognostic and predictive value of tumor infiltrating lymphocytes in breast cancer: a systemic review and meta-analysis. Clin Transl Oncol 2016; 18: 497-506.
 
16.
Mohammed ZM, Going JJ, Edwarda J, et al. The relationship between components of tumor inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer. Br J Cancer 2012; 107: 864-873.
 
17.
Soslow RA, Han G, Park KJ, et al. Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. Mod Pathol 2012; 25: 625-636.
 
18.
Vinayak S, Gray RJ, Adams S, et al. Association of increased tumor-infiltrating lymphocytes (TILs) with immunomodulatory (IM) triple-negative breast cancer (TNBC) subtype and response to neoadjuvant platinum-based therapy in PrECOG0105. ASCO Annual Meeting. J Clin Oncol 2014; 32: 5s.
 
19.
Adams S, Gray RJ, Demaria S, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 2014; 20: 2959-2966.
 
20.
Apetoh L, Ghiringhelli F, Andrè F, et al. The anticancer immune response: Indispensable for therapeutic success? J Clin Invest 2008; 118: 1991-2001.
 
21.
Casares N, Pequignot MO, Tesniere A, et al. Caspase-dependent immunogenicity of doxorubicine induced tumor cell death. J Exp Med 2005; 202: 1691-1701.
 
eISSN:2084-9869
ISSN:1233-9687
Journals System - logo
Scroll to top